Cullinan Oncology Inc — Cash Flow (NASDAQ:CGEM) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -43.43 M-126.66 M-134.28 M-145.3 M-175.75 M -175.75 M Cash from investing activities -333.77 M248.97 M35.81 M-136.31 M179.99 M 179.99 M Cash from financing activities 268.78 M-25.93 M40.75 M266.19 M1.09 M 1.09 M Free cash flow -43.43 M-127.8 M-134.48 M-145.3 M-175.8 M -175.76 M

Haberler

Clear Street, Gilead anlaşmasıyla Cullinan Oncology hissesi için tavsiyesini yineledi

Stifel, Cullinan Oncology’nin hisse hedefini yükseltti

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

Guggenheim, Cullinan Oncology hissesini Al tavsiyesi ve 30 dolar hedef fiyatla takibe aldı

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

Cullinan Therapeutics, önemli otoimmün programları için veri açıklamaları planlıyor